Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 4/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 5/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.54 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763738 | 0.96 | RNASEL (0.57) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL22678645 | 0.96 | RNASEL (0.57) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL21163271 | 0.88 | TGM2 (0.77) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL21163269 | 0.88 | TGM2 (0.77) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL25567646 | 0.87 | TGM2 (0.69) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL6512071 | 0.87 | TGM2 (0.69) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL1533923 | 0.87 | TGM2 (0.69) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL4011876 | 0.87 | TGM2 (0.69) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL1533928 | 0.87 | TGM2 (0.69) | TGM2FUT5KRASRNASELNT5E | |
| SCHEMBL23176397 | 0.86 | TGM2 (0.70) | TGM2FUT5KRASRNASELNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200362382-A1 | METHODS OF PREPARING MODIFIED RNA | MODERNATX, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2019036638-A1 | METHODS OF PREPARING MODIFIED RNA | MODERNATX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362382-A1 | METHODS OF PREPARING MODIFIED RNA | RNGTT, RNMT, NSUN2 | TGM2 3899/4885FUT5 1241/4885KRAS 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.